Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Love it!
Perseverance….is my motto too.
Lol…You are funny!!! Love the sayings!
Busy busy busy bee!!
awesome movement happening this afternoon!
Do you have a link to the announcement? Please share??
Lol….yep! Telling on myself how long I’ve been at this.
Thanks for clarification Lakota. Times have changed over last several decades….lol. My bad. Good luck!!
Can’t margin penny stocks.
Figured….thanks!
Really? .26 to $40. Or do you really mean .40?
Let’s fill opening gap folks.
Always a GOOD thing!
Long term gains still holding 1.5mm shares.
Nice day.
Nice!
Happy New Year from Fisker!
We’ve had an electrifying year in 2021 and are looking forward to driving toward a clean future with you in 2022. ?
Thank you for continuing to support our brand and our mission.
VISION
A clean future for all.
MISSION
Create the world's most emotional & sustainable vehicles.
Who’s taking the million plus blocks at .0019?
Ditto!
Cannagistics Inc (OTCMKTS:CNGT) Stock Goes Parabolic : Rockets 780% In a Week
Posted By Mavis Babcock on December 31, 2021
One of the stocks to have managed to make a massive move over the course of the past week is that of Cannagistics Inc (OTCMKTS:CNGT) and the trend remained the same on Thursday as the stock ended the day with gains of as much as 19%.
Trading Data
On Thursday, CNGT stock jumped 19% to close at $0.0132 with more than 176.15 million shares, compared to its average volume of 9.9 million shares. The stock has moved within a range of $0.0105 – 0.0240 after opening trade at $0.0123.
Closes Acquisition of The Integrity Wellness Group, Inc.
In this context, it is also important to point out that the rally on Thursday took the gains generated by the stock over the past week to a staggering 780%. In this situation, it should be noted that there has been no news about the company at all over the past month or so and hence, the rally might appear speculative to many.
However, it might be a good idea to take a look at a development in relation to Cannagistics from November 12. At the time, the company announced that it had managed to close the transaction for the acquisition of The Integrity Wellness Group Inc from Availa Bio Inc.
The company completed the acquisition in exchange for the controlling stake in The Integrity Wellness Group Inc, which is going to be a newly recognised public unit. However, it is still unclear if the latest rally had been related to that deal.
Key Quote
Rob Gielt the President and CEO of CNGT (Integrity Wellness), said, “I am very much looking forward to working with this eclectic group of extremely qualified individuals, backed by science, and years of working with health and wellness products. I am excited to be using my skill set in marketing to advance the development and promotion of the many products of this company.”
Technical Data
CNGT stock is above the 20-Day and 50-Day Moving averages of $0.0039 and $0.0045 respectively. However, the stock is trading below the 200-Day moving average of $0.0230. The stock is up 780% in the past month.
Good insight….thanks!
Who buys 1 or 25 shares of a .015 penny stock….weird!
25% of today’s total traded volume hit at days end. Single 2,000,000 block.
This stock truly does suck. Owners/Management….come on now!!
Nice!
Lots of large block buys going into the close.
Great entry point!
UPDATE -- Revive Therapeutics Expands Bucillamine Research to Treat Omicron Variant and Adds Inflammatory Markers to FDA Phase 3 Clinical Trial
9:31 AM ET 12/3/21 | GlobeNewswire
UPDATE -- Revive Therapeutics Expands Bucillamine Research to Treat Omicron Variant and Adds Inflammatory Markers to FDA Phase 3 Clinical Trial
-- Expanding the potential of Bucillamine as an effective treatment for
Omicron variant (B.1.1.529)
-- Bucillamine shown to inhibit SARS-CoV-2 infection in vitro for the Delta
variant (B.1.617.2)
-- Adding inflammatory markers along with viral load testing to current
Phase 3 clinical study for COVID-19 aiming to strengthen Bucillamine's
profile as both an anti-viral and anti-inflammatory agent for infectious
diseases
TORONTO, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the Company has decided to expand research with Bucillamine, an oral drug shown to have promising anti-viral and anti-inflammatory capabilities and is being evaluated in a current Phase 3 clinical study for COVID-19, as a potential treatment for the Omicron variant (B.1.1.529).
The expansion to explore Bucillamine's therapeutic potential for the Omicron variant is supported from a recent research study published, titled "Thiol drugs decrease SARS-CoV-2 lung injury in vivo and disrupt SARS-CoV-2 spike complex binding to ACE2 in vitro" from the University of California, San Francisco, which revealed that potent thiol drugs, like Bucillamine, inhibit SARS-CoV-2 infection in vitro, specifically the Delta variant (B.1.617.2) and also reduces SARS-CoV-2-related lung injury in vivo and provides a strong rationale for trials of systemically delivered thiol drugs as COVID-19 treatments. In addition, thiol-based drugs, like Bucillamine, have been shown in research models to decrease the binding of SARS-CoV-2 spike protein to its receptor, decrease the entry efficiency of SARS-CoV-2 spike pseudotyped virus, and inhibit SARS-CoV-2 live virus infection. The Company supported recent research to explore the utility of thiol-based drugs under its sponsored research agreement with the University of California, San Francisco ("UCSF") in the laboratory of Dr. John Fahy. For a copy of the research paper, visit https://www.biorxiv.org/content/10.1101/2020.12.08.415505v2.full.pdf
In a study that evaluated the role of pro-inflammatory cytokines that are highly upregulated in patients with COVID-19 in inducing inflammatory cell death, inflammation, tissue and organ damage, and mortality showed that the specific combination of tumor necrosis factor (TNF-) and interferon (IFN-) is critical for these processes. Furthermore, it was found that inhibiting TNF- and IFN- protected against death in SARS-CoV-2 infection and models of sepsis, hemophagocytic lymphohistiocytosis (HLH), and cytokine shock, suggesting that this pathway can be applicable beyond COVID-19 in infectious and inflammatory diseases where TNF- and IFN--mediated inflammatory cell death drive the pathology (Karki, Rajendra et al. 2020).
There is evidence that Bucillamine inhibits pro-inflammatory cytokine production and transendothelial T-cell migration, both of which could further dampen disease course in COVID-19 (Horowitz LD. 2003, Munakata Y. 2000). As a result of the research and the rise of the Delta variant and Omicron variant, the Company has decided that in addition to incorporating viral load testing, which it announced on November 16, 2021, it will also be adding inflammatory markers to complement the ongoing Phase 3 clinical trial (ClinicalTrials.gov Identifier: NCT04504734) evaluating the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19. These inflammatory markers will allow the Company to understand Bucillamine's potential as an anti-inflammatory agent in the treatment course and provide confidence in the potential utility and effectiveness of Bucillamine in COVID-19.
Michael Frank, CEO of the Company, commented, "Bucillamine has thus far shown in published research to be agnostic as a potential treatment to certain COVID-19 variants, including the Delta variant, and with the rise of the Omicron variant, we are motivated in expanding research with Bucillamine to explore its therapeutic utility for the Omicron variant. In addition, we are incorporating inflammatory markers to complement the viral load testing to our remaining patients in our ongoing Phase 3 study to support Bucillamine as a safe and effective anti-inflammatory and anti-viral oral agent for mild to moderate COVID-19."
The Company is not making any express or implied claims that its product has the ability to eliminate or cure COVID-19 (SARS-2 Coronavirus) at this time.
Where is everyone?
Nice close.
Appears to be solid retail buying this morning!
Mandate should be overturned by SC
Nothing but sells on the trading block.
Sello do you see any light at the end of the tunnel….this black hole?
Gig Em!
Anyone ready for the next leg up?
Would be nice!
This stock sure is sucking wind!
Good morning to all! In need of some positivity it’s morning. How will the good news for an NRX translate over to Relief?
When?
Which company does AI robot Janet belong to? She’s made Denny’s news